Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vunakizumab in active spondyloarthritis
NCT06770088Phase 4Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 4 trial of vunakizumab in spondyloarthritis (SpA), sponsored by Sun Yat-sen University. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
vunakizumab
03
Conditions
spondyloarthritis (SpA)
Beyond the preview
Go deeper on NCT06770088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06770088.